MAVACAMTEN: A door that has opened in the treatment of Hypertrophic Cardiomyopathy

J Pak Med Assoc. 2023 Feb;73(2):446-447. doi: 10.47391/JPMA.7258.
No abstract available

Publication types

  • Letter

MeSH terms

  • Benzylamines*
  • Cardiomyopathy, Hypertrophic* / therapy
  • Humans
  • Uracil

Substances

  • MYK-461
  • Benzylamines
  • Uracil